NewBridge Pharmaceuticals at EASL 2019
May 01, 2019
NewBridge President and CEO Joe Henein, Business Director Group Franchise Hisham EL Sayed and Brand Manager Rare Diseases Jennifer Bteich, attended The International Liver Congress “EASL 2019”, that was held in Vienna-Austria from April 10-14th along with Intercept team.
This year, EASL witnessed one of the most exciting and biggest study about NASH (Non-Alcoholic Steatohepatitis) that was presented for the first time during the congress.
